With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take ...

LEO Pharma has applied to the EMA to expand the label for Anzupgo (delgocitinib) cream to include adolescents.

In today's economic landscape, where inflation and rising interest rates are a constant concern, companies are compelled to prioritize efficiency and cash flow management. This focus is essential not ...

Pulse Health Sciences is the medical education and insights division of Match Health Collective. Pulse designs structured, evidence-based peer-to-peer programs that help clinicians interpret emerging ...

The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...

Founded in 1964, Alger is recognized as a pioneer of growth-style investment management. Privately-owned and headquartered in New York City, Alger can help "Unlock Your Growth Potential" through a ...

Fintel reports that on December 16, 2025, Stifel maintained coverage of Mirum Pharmaceuticals (NasdaqGM:MIRM) with a Buy ...

In today’s ACT Brief, we close out our McKinsey interview series with a look at how AI could transform clinical trials end to ...

Royalty Pharma is acquiring a low-single digit pre-existing royalty on worldwide net sales on each of Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. The ...